Pair Name	Camptothecin, Sorafenib
Partner Name	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	ABCG2	hsa9429
	Down-regulation	Expression	MT1G	hsa4495
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	SLC7A11	hsa23657
	Down-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
Result	The synergetic combination significantly increases lipid peroxidation and iron concentration, decreases TAC, GPX4 and GR activity, and reduces the expression of both Nrf2 and SLC7A11. The downregulation of Nrf2 expression has a vital role in the reduction of resistance mediators to sorafenib against HCC cells like (p62, MT1G, and ABCG2) and improves the cellular uptake of sorafenib. The current study provided evidence that Nrf2 inhibition by CPT improves sorafenib's sensitivity and reduces sorafenib's resistance via the augmentation of sorafenib's ferroptosis action.

Pair Name	Camptothecin, Rapamycin
Partner Name	Rapamycin
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Up-regulation	Expression	ATG5	hsa9474
	Up-regulation	Activity	CASP9	hsa842
	Up-regulation	Expression	MAP1LC3B	hsa81631
In Vitro Model	SK-OV-3	Ovarian serous cystadenocarcinoma	Homo sapiens (Human)	CVCL_0532
In Vivo Model	Cells suspended in PBS were subcutaneously injected into the right back of mice.
Result	Autophagy-induced intracellular signaling fractional nano-drug system for synergistic anti-tumor therapy

Pair Name	Camptothecin, Camptosar
Partner Name	Camptosar
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Up-regulation	Expression	CALR	hsa811
	Up-regulation	Expression	CD8A	hsa925
	Up-regulation	Expression	GZMB	hsa3002
	Up-regulation	Expression	HMGB1	hsa3146
	Up-regulation	Expression	IFNG	hsa3458
	Up-regulation	Expression	LRP1	hsa4035
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vivo Model	2×10⁵ of 4T1-Luc2 cells (DMEM/Matrigel, 3/1, v/v) were inoculated into the 2nd mammary fat pad of Balb/c mice directly without surgery.
Result	Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy

Pair Name	Camptothecin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2A00-2F9Z]	Solid tumour or cancer		Investigative
Gene Regulation	Up-regulation	Expression	CTNNB1	hsa1499
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
	BT-474	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0179
In Vivo Model	Tumor inoculation was achieved by subcutaneously injecting 5×10⁴ 4T1 cells in the abdominal mammary gland of female BALB/c mice in order to prevent interference with normal bodily functions.
Result	Camptothecin-doxorubicin combinations showed synergistic antitumor acitivity.